New inhaled drug shows promise in preventing deadly fungus in lung transplant patients
NCT ID NCT05037851
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tested a new inhaled medication called opelconazole (PC945) to prevent a serious fungal lung infection (aspergillosis) in people who had a lung transplant. The trial included 102 participants and compared the safety and tolerability of the new drug against standard care over 12 weeks. The goal was to see if this treatment could be a safer or more effective way to protect transplant recipients from this dangerous infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Phoenix, Arizona, 85013, United States
-
Clinical Research Site
La Jolla, California, 92037, United States
-
Clinical Research Site
Los Angeles, California, 90095, United States
-
Clinical Research Site
Jacksonville, Florida, 32224, United States
-
Clinical Research Site
Tampa, Florida, 33606, United States
-
Clinical Research Site
Maywood, Illinois, 60153, United States
-
Clinical Research Site
New York, New York, 10016, United States
-
Clinical Research Site
The Bronx, New York, 10467, United States
-
Clinical Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Clinical Research Site
Philadelphia, Pennsylvania, 19140, United States
-
Clinical Research Site
Pittsburgh, Pennsylvania, 15213, United States
-
Clinical Research Site
Nashville, Tennessee, 37232, United States
-
Clinical Research Site
Dallas, Texas, 75246, United States
-
Clinical Research Site
Edmonton, T6G 1Z1, Canada
-
Clinical Research Site
Toronto, M5G 2N2, Canada
-
Clinical Research Site 1
Houston, Texas, 77030, United States
-
Clinical Research Site 2
Houston, Texas, 77030, United States
-
Clinical Research Site 3
Houston, Texas, 77030, United States
-
Research Site
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.